SIRT2 and neoplasm: By transfecting wild‐type or dead‐enzyme mutants of SIRT1 or SIRT2 into tumour cells, we found that the loss of SIRT2 deacetylase activity resulted in consistent levels of LIFR‐K620 acetylation (Figure 2I).